Viyash Scientifi

how big is Sequent Scien.?

As of Jun 06, Sequent Scientific Ltd has a market capitalization of 4,710.68 Cr, with net sales of 1,551.37 Cr and a net profit of 21.88 Cr for the latest four quarters. Shareholder's funds are 656.56 Cr, and total assets are 1,462.03 Cr as of Mar 2024.

Market Cap: As of Jun 06, Sequent Scientific Ltd has a market capitalization of 4,710.68 Cr, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Sequent Scientific Ltd reported net sales of 1,551.37 Cr and a net profit of 21.88 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: The balance sheet data is also on a Consolidated basis for the latest annual period ending in Mar 2024. Shareholder's funds are reported at 656.56 Cr, while total assets amount to 1,462.03 Cr.

Who are in the management team of Sequent Scien.?

As of March 2023, the management team of Sequent Scien includes Kausalya Santhanam (Non-Executive & Independent Director), Sharat Narasapur (Joint Managing Director), N Rajaram (Managing Director & CEO), and several other non-executive directors. The team features a mix of executive and independent roles.

As of March 2023, the management team of Sequent Scien includes the following members:<BR><BR>1. Kausalya Santhanam - Non-Executive & Independent Director<BR>2. Sharat Narasapur - Joint Managing Director<BR>3. Krunal Shah - Company Secretary & Compliance Officer<BR>4. Neeraj Bharadwaj - Non-Executive & Non-Independent Director<BR>5. Gregory John Andrews - Non-Executive & Non-Independent Director<BR>6. Fabian Kausche - Non-Executive & Non-Independent Director<BR>7. Kamal K Sharma - Chairman & Independent Director<BR>8. Milind Sarwate - Non-Executive & Independent Director<BR>9. N Rajaram - Managing Director & CEO<BR>10. Hari Babu Bodepudi - Director<BR><BR>This team comprises a mix of executive and non-executive directors, with roles ranging from managing director to independent directors.

What does Sequent Scien. do?

Sequent Scientific Ltd is a small-cap integrated pharmaceutical company specializing in the Pharmaceuticals & Biotechnology sector, with net sales of 402 Cr and a net profit of 9 Cr reported for March 2025. The company has a market cap of Rs 4,706 Cr and key financial metrics include a P/E ratio of 186.00 and a debt-equity ratio of 0.59.

Overview: <BR>Sequent Scientific Ltd is a leading integrated pharmaceutical company operating in the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap.<BR><BR>History: <BR>Sequent Scientific Ltd was originally incorporated as 'P I Drugs & Pharmaceuticals Limited' in 1995 and changed its name to 'Sequent Scientific Limited' in 2009. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 402 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 9 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 4,706 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 186.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.59 <BR>Return on Equity: 3.66% <BR>Price to Book: 6.83 <BR><BR>Contact Details: <BR>Address: 301 Dosti Pinnacle 3rd Floor, Plot E7 Road No 22 Wagle Indl Thane Maharashtra : 400604 <BR>Tel: 91-022-41114777 <BR>Email: investors@sequent.in <BR>Website: http://www.sequent.in

Has Sequent Scien. declared dividend?

Sequent Scientific Ltd has declared a 25% dividend, amounting to ₹0.5 per share, with an ex-date of September 8, 2021. Despite the dividend declaration, the dividend yield is 0%, and total returns have varied significantly across different periods.

Sequent Scientific Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 0.5<BR>- Ex-date: 08 Sep 21<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -4.24%, the dividend return was 0%, resulting in a total return of -4.24%.<BR><BR>For the 1-year period, the price return was 55.68%, the dividend return was 0%, leading to a total return of 55.68%.<BR><BR>Over the 2-year period, the price return was 155.28%, with a dividend return of 0%, resulting in a total return of 155.28%.<BR><BR>In the 3-year period, the price return was 74.41%, the dividend return was 0%, which culminated in a total return of 74.41%.<BR><BR>During the 4-year period, the price return was -27.53%, the dividend return was 0.17%, leading to a total return of -27.36%.<BR><BR>For the 5-year period, the price return was 110.09%, the dividend return was 0.52%, resulting in a total return of 110.61%.<BR><BR>Overall, Sequent Scientific Ltd has declared a dividend, but the dividend yield remains at 0%. The total returns over various periods show significant variability, with strong returns in the 1-year and 2-year periods, while the 4-year period experienced a decline.

Who are the peers of the Sequent Scien.?

Sequent Scien.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Hikal, Aarti Drugs, Unichem Labs, and Dishman Carbogen. Sequent Scien. has an average management risk and below average growth, with a 1-year return of 85.27%, outperforming its peers.

Peers: The peers of Sequent Scien. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Hikal, Aarti Drugs, Unichem Labs., and Dishman Carbogen.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Hikal, Aarti Drugs, and the rest. Average management risk is found at Sequent Scien., Unichem Labs., and Dishman Carbogen. Growth is excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is noted at Divi's Lab., Torrent Pharma, Sequent Scien., Hikal, Aarti Drugs, and the rest. Capital structure is excellent at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while below average capital structure is found at Sequent Scien. and Dishman Carbogen, with average capital structure at Hikal and Unichem Labs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the peer with the lowest is Aarti Drugs at -3.81%. Sequent Scien.'s 1-year return is 85.27%, which is significantly higher than all peers. Additionally, Hikal, Unichem Labs., and Dishman Carbogen have negative six-month returns.

Who are the top shareholders of the Sequent Scien.?

The top shareholder of Sequent Scientific is Ca Harbor Investments, holding 52.61%. Other significant shareholders include mutual funds at 10.22%, foreign institutional investors at 6.05%, and individual investors at 23.43%.

The top shareholders of Sequent Scien. include a mix of promoters and institutional investors. The largest shareholder is Ca Harbor Investments, holding 52.61% of the company. Promoters collectively hold a significant majority, with no pledged promoter holdings reported. <BR><BR>In terms of institutional ownership, mutual funds hold 10.22% across eight schemes, while foreign institutional investors (FIIs) account for 6.05% through 54 different entities. The highest public shareholder is Quant Mutual Fund, specifically the Quant Healthcare Fund, which holds 9.53%. Additionally, individual investors collectively own 23.43% of the company.

How has been the historical performance of Sequent Scien.?

Sequent Scien. has shown a recovery in profitability and sales growth, with net sales increasing to 1,551.37 Cr in Mar'25 and a net profit of 21.88 Cr, up from a loss the previous year. Key financial metrics indicate a stable position, with improved operating profit and cash flow.

Answer:<BR>The historical performance of Sequent Scien. shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Sequent Scien. has experienced a steady increase in net sales, rising from 1,039.31 Cr in Mar'19 to 1,551.37 Cr in Mar'25, with a notable jump from 1,369.73 Cr in Mar'24. Total operating income followed a similar trajectory, reaching 1,551.37 Cr in Mar'25. However, total expenditure also increased, amounting to 1,389.58 Cr in Mar'25, leading to an operating profit of 161.79 Cr, a significant recovery from the previous year's 61.41 Cr. Profit before tax turned positive at 44.31 Cr in Mar'25 after several years of losses, while profit after tax also improved to 32.26 Cr. The company's net profit stood at 21.88 Cr in Mar'25, a recovery from a loss of 35.88 Cr in Mar'24. The earnings per share (EPS) reflected this positive trend, increasing to 0.87 in Mar'25 from -1.44 in Mar'24. On the balance sheet, total assets rose to 1,499.23 Cr in Mar'25, with total liabilities slightly increasing to 1,499.23 Cr, indicating a stable financial position. Cash flow from operating activities improved to 83.00 Cr in Mar'25, contributing to a closing cash balance of 62.00 Cr. Overall, Sequent Scien. has shown resilience with a recovery in profitability and sales growth, despite challenges in previous years.

Is Sequent Scien. overvalued or undervalued?

As of December 1, 2025, Sequent Scientific is fairly valued with a PE ratio of 126.16, an EV to EBITDA of 31.90, and a ROCE of 10.17%, despite its higher valuation compared to peers like Cipla and Dr. Reddy's Labs, while achieving a year-to-date return of 25.71%, significantly outperforming the Sensex's 9.60%.

As of 1 December 2025, the valuation grade for Sequent Scientific has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 126.16, an EV to EBITDA of 31.90, and a ROCE of 10.17%. <BR><BR>In comparison to its peers, Sequent Scientific's PE ratio is significantly higher than that of Cipla, which stands at 22.63, and Dr. Reddy's Labs at 18.22, both of which are considered attractive. Despite its high valuation ratios, the company's recent performance shows a year-to-date return of 25.71%, outperforming the Sensex's 9.60%, indicating strong market confidence in its growth potential.

Is Sequent Scien. technically bullish or bearish?

As of December 2, 2025, the trend is mildly bullish, supported by bullish MACD indicators and moving averages, but mixed signals from KST and Dow Theory suggest caution.

As of 2 December 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the weekly and monthly MACD indicators which are both bullish, and the daily moving averages indicating bullish momentum. However, the KST shows a mixed signal with weekly bullishness and monthly mild bearishness, while Dow Theory indicates a mildly bearish stance on the weekly timeframe. The Bollinger Bands also reflect a mildly bullish trend on both weekly and monthly charts. Overall, while there are bullish indicators, the presence of mixed signals suggests caution.

When is the next results date for Sequent Scientific Ltd?

The next results date for Sequent Scientific Ltd is February 5, 2026.

The next results date for Sequent Scientific Ltd is scheduled for February 5, 2026.

Are Viyash Scientific Ltd latest results good or bad?

Viyash Scientific Ltd's latest results show strong revenue growth with ₹858.41 crores in Q3 FY26, but a significant net profit decline of 29.99% raises concerns about profitability sustainability. Overall, the mixed performance suggests caution for investors.

Viyash Scientific Ltd's latest results present a mixed picture. On one hand, the company achieved record revenue of ₹858.41 crores in Q3 FY26, marking a 10.90% increase year-on-year and a slight 0.95% rise quarter-on-quarter. This indicates a strong top-line performance and suggests that the company is successfully capturing market share in the animal health pharmaceutical segment.<BR><BR>However, the net profit tells a different story. The consolidated net profit for the quarter was ₹38.44 crores, which represents a significant decline of 29.99% from the previous quarter and a 13.83% drop compared to the same quarter last year. This decline in profitability raises concerns about the sustainability of earnings, especially given the company's history of profit volatility.<BR><BR>While the operating margin improved to 20.46%, the profit after tax (PAT) margin decreased to 5.65%, highlighting the impact of higher tax expenses and depreciation on the bottom line. The market has reacted negatively, with the stock price declining by 3.92% following the results, reflecting investor concerns about the company's high valuation multiples and profit fluctuations.<BR><BR>In summary, while Viyash Scientific has demonstrated operational improvements and revenue growth, the significant drop in net profit and ongoing volatility in earnings suggest that the latest results are more concerning than positive. Investors should approach this situation with caution, considering both the operational strengths and the challenges in profitability.

Should I buy, sell or hold Viyash Scientific Ltd?

Why is Viyash Scientific Ltd falling/rising?

As of 08-May, Viyash Scientific Ltd's stock price is at 219.00, reflecting a 1.26% decline after two days of gains. Despite strong historical performance and financial stability, the current drop is influenced by short-term market dynamics and underperformance relative to its sector.

As of 08-May, Viyash Scientific Ltd's stock price is currently at 219.00, reflecting a decrease of 2.8, or 1.26%. This decline follows a trend reversal after two consecutive days of gains, indicating a short-term pullback in the stock's performance. Despite this drop, the stock has shown strong performance over various periods, including a 41.20% increase over the past year and a remarkable 171.44% rise over the last three years, significantly outperforming the Sensex during these times.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 0.55%, which may contribute to the current price decline. Additionally, the weighted average price suggests that more volume was traded close to the low price, indicating selling pressure. However, it is noteworthy that investor participation has risen, with delivery volume increasing by 90.29% against the five-day average, which could suggest underlying interest despite the current price drop.<BR><BR>On the positive side, Viyash Scientific Ltd has consistently declared strong results over the last eight quarters, with a significant growth in operating profit of 78.2% reported in December. The company also boasts a high return on capital employed (ROCE) of 18.65% and a low debt-equity ratio of 0.61 times, indicating financial stability. However, the stock faces challenges due to weak long-term fundamental strength, with an average ROCE of only 7.40% and a high debt to EBITDA ratio of 1.32 times, which may deter long-term investors.<BR><BR>In summary, while Viyash Scientific Ltd has demonstrated strong historical performance and positive financial metrics, the current price decline can be attributed to short-term market dynamics, recent underperformance relative to its sector, and concerns regarding its long-term growth potential.

Which are the latest news on Viyash Scientifi?